Written by MarketBeatUpdated September 4, 2025 ShareLink copied to clipboard. Key Points Allogene Therapeutics has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a shift in investor sentiment. The company’s current market cap is approximately $250.72 million, with a price target consensus of $8.44 after mix ratings from various analysts. Allogene Therapeutics reported earnings of ($0.23) per share, outperforming analysts' expectations by $0.05, and is set to post an estimated -1.28 EPS for the current fiscal year. Five stocks to consider instead of Allogene Therapeutics. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and OffersJoby Aviation's Pullback: A Gift for Investors Who See the FutureBy Jeffrey Neal Johnson | September 2, 2025Stunning new initiative unfolding in the White House?From Paradigm Press (Ad)Morgan Stanley Issues Positive Forecast for Lucid Group (NASDAQ:LCID) Stock PriceBy MarketBeat | September 6, 2025Top 5 September Stock Picks: Market Tailwinds Drive New MomentumBy Thomas Hughes | September 1, 2025lululemon athletica (NASDAQ:LULU) Given New $150.00 Price Target at Jefferies Financial GroupBy MarketBeat | September 6, 2025Capital Gains Tax Strategies for SeniorsFrom SmartAsset (Ad)3 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Auto Tariffs Are Coming Down: 3 Stocks to Benefit SoonBy Gabriel Osorio-Mazilli | August 31, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated September 4, 2025 ShareLink copied to clipboard. Key Points Allogene Therapeutics has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a shift in investor sentiment. The company’s current market cap is approximately $250.72 million, with a price target consensus of $8.44 after mix ratings from various analysts. Allogene Therapeutics reported earnings of ($0.23) per share, outperforming analysts' expectations by $0.05, and is set to post an estimated -1.28 EPS for the current fiscal year. Five stocks to consider instead of Allogene Therapeutics. Like this article? Share it with a colleague. Link copied to clipboard.
